Contents

February 2012 • Volume 6 Number 1

3 Editorial comment
Tracy Crooks

4 Successful commercialisation of a REMS program introduction
Whist clinical and commercial responsibilities within a company apply to different teams, risk management and mitigation strategies are central to both
Caroline York and Jean Dinwiddie

10 Cost versus quality – the real price you could pay for ‘budget’ PV
With pharmacovigilance, it is false economy to choose PV services based on cost rather than quality.
Steve Proudlove

12 Adverse effects of vaccines – is there a causal relationship?
The US Institutes of Medicine found evidence for a causal relationship between some vaccines and some adverse effects. But concluded that few health problems can be linked to vaccines.

14 Product liability insurance for the life sciences industries
The author, an insurance broker and risk adviser, explains how risks, especially product liability risk, are dealt with by insurance companies.
Christopher Bryce

18 Evolution of the Japanese Regulatory System
Japan has reorganised its drug regulatory system to form a single unified agency similar to that of Europe and the USA. Clinical data requirements and vigilances are now clearly defined.
David Jeffreys